RA Capital Management’s Vor Biopharma VOR Stock Holding History

RA Capital Management’s Portfolio VOR Stock Details VOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$44.2M	Sell	2,402,095 -3,002,903	-56%	-$45.4M	0.38%	42
2026 Q1	$96.4M	Hold	5,404,998	–	–	1.02%	22
2025 Q4	$70.7M	Buy	5,404,998 +3,422,697	+173%	+$63.7M	0.72%	26
2025 Q3	$96.6M	Sell	1,982,301 -1	-0%	-$40	1.19%	23
2025 Q2	$64.2M	Hold	1,982,302	–	–	1.08%	24
2025 Q1	$28.4M	Hold	1,982,302	–	–	0.48%	33
2024 Q4	$44M	Buy	1,982,302 +844,858	+74%	+$14M	0.59%	36
2024 Q3	$15.9M	Hold	1,137,444	–	–	0.18%	58
2024 Q2	$22.7M	Hold	1,137,444	–	–	0.3%	50
2024 Q1	$53.9M	Hold	1,137,444	–	–	0.69%	40
2023 Q4	$51.2M	Hold	1,137,444	–	–	0.8%	32
2023 Q3	$48.2M	Hold	1,137,444	–	–	0.95%	31
2023 Q2	$70.3M	Hold	1,137,444	–	–	1.33%	23
2023 Q1	$122M	Hold	1,137,444	–	–	2.77%	9
2022 Q4	$151M	Buy	1,137,444 +581,395	+105%	+$57.5M	3.07%	8
2022 Q3	$44.3M	Hold	556,049	–	–	0.94%	36
2022 Q2	$55.3M	Hold	556,049	–	–	1.47%	21
2022 Q1	$67.2M	Hold	556,049	–	–	1.47%	19
2021 Q4	$129M	Hold	556,049	–	–	2.28%	11
2021 Q3	$174M	Hold	556,049	–	–	2.42%	9
2021 Q2	$207M	Hold	556,049	–	–	3.33%	5
2021 Q1	$479M	Buy	+556,049	New	+$470M	7.23%	3

Other funds holding VOR

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

RA Capital Management's VOR Position: Q2 2026 in Review

RA Capital Management reduced its Vor Biopharma (VOR) stake by 56% in Q2 2026, selling an estimated $45.4M and leaving 2,402,095 shares worth $44.2M. The position accounts for 0.38% of the portfolio, ranked #42.

RA Capital Management first reported a position in VOR in Q1 2021 and has held it in 22 quarters since. The position peaked at $479M in Q1 2021. 102 funds tracked by Wall St. Rank hold VOR as of Q2 2026.

RA Capital Management held 2,402,095 shares of Vor Biopharma worth $44.2M as of Q2 2026.
RA Capital Management sold 3,002,903 Vor Biopharma shares in Q2 2026, an estimated $45.4M.
Vor Biopharma made up 0.38% of RA Capital Management's portfolio in Q2 2026, its #42 holding.
RA Capital Management first reported a position in Vor Biopharma in Q1 2021 and has held it in 22 quarters since.
RA Capital Management's Vor Biopharma position peaked at $479M in Q1 2021.
102 funds tracked by Wall St. Rank held Vor Biopharma as of Q2 2026.

Based on RA Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.